Transplantation of stem or progenitor cells is an attractive new approach for treating neurodegenerative conditions of the central nervous system, which aims to protect or replace neurons and improve function. Proof of principle has already been shown in the retina that photoreceptors may be replaced by transplantation of neural progenitor cells. However, the task of retinal ganglion cell replacement is much more complex, as new cells will need to establish complex connections within the retina and also extend axons to precise targets in the brain. Although progress has been made in this field, it is likely that neuroprotective clinical applications will be established more quickly. Our laboratory has focused on the intraocular transplantation of cells to treat inner retinal disease, either by neuronal replacement or neuroprotection of existing cells. We have investigated the efficacy and effects of transplanting a variety of cell types, including human Mü ller stem cells (MIO-M1), oligodendrocyte precursor cells (OPCs), and bone marrow-derived mesenchymal stromal cells (MSCs) in a rat model of experimentally induced glaucoma. We also have developed and characterized a novel in vitro organotypic retinal explant culture system for exploring the methods of enhancing the efficacy of cell transplantation for the inner retina. In this review, we discuss the potentially beneficial effects of intraocular cell injections, identify current shortcomings of retinal stem cell therapy, and suggest directions for future research.
Introduction
Inner retinal diseases pose a major threat to vision throughout the world. Glaucoma, the most common neurodegenerative condition of the inner retina, is estimated to affect over 60 million people globally and to cause bilateral blindness in more than 14% of them. 1 Reducing intraocular pressure (IOP) is the only clinically proven method of slowing the progression of glaucoma, 2 but ocular hypotensive therapy for this disease is insufficient in some patients as it fails to halt visual deterioration. For these patients, neuroprotective treatments that can support surviving retinal ganglion cells (RGCs) might offer a new avenue to preserve vision. However, due to the insidious character of glaucomatous onset and progression, many affected patients experience significant vision loss even before diagnosis and treatment can occur. Therefore, novel therapies that are capable of restoring vision are also of interest. Indeed, glaucoma may not be the only inner retinal condition that would benefit from therapeutic approaches that address these issues. It is possible that the findings discussed in this review may be applicable to other diseases that result in the death or dysfunction of RGCs, such as ischaemic optic neuropathy, optic neuritis, or the inherited mitochondrial optic neuropathies.
Transplantation of stem and progenitor cells is of great interest in the context of treating neurodegenerative disease in general, and in the retina in particular, because it may confer therapeutic benefit through both neuroprotective and cell replacement mechanisms. [3] [4] [5] [6] In the outer retina, the regenerative potential of cell transplantation has already been shown. Subretinal injection of photoreceptor progenitors obtained from mice at an optimal developmental stage permitted photoreceptor differentiation, integration of grafted cells, and functional recovery in rhodopsin-deficient host mice. 7, 8 Of course, the targeted replacement of RGCs is a more complex task than the replacement of photoreceptors, as RGC regeneration requires differentiation into a cell type with highly specialized properties, the establishment of numerous synaptic inputs, and the extension of an extremely long axon to precise brain targets in a manner that preserves the retinotopic map.
The prerequisites for successful cell transplantation to achieve neuroprotective goals are more modest and consist mainly of translocation into retinal tissue, long-term survival, and the provision of neurotrophic support for the host tissue. Indeed, some reports suggest that intraocular cell transplantation could benefit a variety of neurodegenerative conditions of the inner and outer retina by providing trophic support to surviving tissue [9] [10] [11] [12] or stimulating endogenous support mechanisms. 13, 14 However, outstanding problems remain before inner retinal cell therapy in either context (regenerative or neuroprotective) will be a feasible clinical treatment optionFWhat types of cells should be transplanted? Is transplantation into the eye sufficient to achieve an optimal therapeutic effect? What can be done to improve the efficacy of stem cell therapy for the inner retina? Here, we examine some of the research from our laboratory, which addresses the prospects for cell transplantation to treat diseases of the inner retina.
Transplantation of MIO-M1 stem cells
In 2002, Limb et al 15 described a spontaneously immortalized cell line derived from the Mü ller glia of a postmortem human retina, which they designated MIO-M1. More recently, they showed that this and other similar cell lines are multipotent and capable of differentiating into neurons with a retinal phenotype. 16 These data suggest that the adult human retina may harbour a population of cells that could be utilized for cell therapy. As such, we sought to study the behaviour of these cells after transplantation into glaucomatous rat eyes.
We found that xenotransplantation into either the vitreous or subretinal space without immune suppression resulted in the rapid rejection of grafted cells. In contrast, subsequent triple immunosuppressive therapy greatly enhanced cell survival. 17 Histology revealed that grafted cells tended to remain as a bolus at the site of injection without any substantial integration into the host neural tissue (Figure 1a ). However, intraocular administration of erythropoietin or chondroitinase ABC modestly increased the number of cells able to migrate into the retinal tissue ( Figure 1b ). In addition, although integrated cells extended processes into adjacent layers of the retina, they failed to exhibit any markers of differentiation. Occasionally, intravitreally engrafted cells expressed the neuronal marker b-III tubulin or the astrocytic marker GFAP, but robust differentiation of the transplant was not observed. These results are an encouraging demonstration that intraocular cell transplantation is feasible in a rat model of glaucoma, but also indicate that manipulation of the cells and/or host environment before transplantation will be necessary to optimize therapeutic results.
Transplantation of oligodendrocyte precursor cells (OPCs)
Having developed a reliable in vivo system with which to study retinal cell therapy, we opted to expand the pool of our graft sources to include OPCs isolated from the neonatal rat brain. OPCs have previously been shown to myelinate RGC axons when transplanted into the rat eye concomitant with an 'activating' inflammatory trigger. 18 OPCs have also previously shown a neuroprotective capacity in vitro through neurotrophic factor secretion. 19 Thus, we were interested to know whether either of these phenomena would confer neuroprotection to RGCs upon OPC transplantation into glaucomatous eyes.
In this case, syngeneic transplants using inbred Lewis rats were utilized in the absence of immune suppression to limit graft rejection and avoid potential complication introduced by administration of immunosuppressive drugs. Syngeneic transplantation resulted in graft survival through the 12-week duration of our study. Transplantation of OPCs alone, either 8 weeks before or concurrent with the onset of glaucoma, did not offer any neuroprotective effect. However, coinjection of OPCs and an inflammatory stimulus increased axonal survival by approximately 50 percent. 20 Moreover, we observed that the engrafted cells differentiated into mature oligodendrocytes (as expected) and produced cells that expressed GFAP or b-III tubulin, suggestive of astrocytic or neuronal differentiation, respectively. Interestingly, limited myelination of RGC axons by differentiating OPCs was observed which hinted that the neuroprotective effect was not contact-mediated, but due to the supply of soluble neurotrophic factors. Future research will address the neuroprotective mechanism of OPC transplantation and the potential for OPCs to be used in a regenerative capacity.
A new in vitro model of cell transplantation for the inner retina
The results of our in vivo experiments and that of other laboratories have provided encouraging proof of principle that cell transplantation can have beneficial effects on neurodegenerative conditions of the inner retina. However, they also show the limitations of intraocular cell transplantation. When we transplanted MIO-M1 stem cells or OPCs, we observed minimal retinal integration (o1% of cells) and could not adequately control or encourage the differentiation of engrafted cells. It was also evident that using an in vivo approach to improve the efficacy of intraocular transplantation was problematic as we encountered graft rejection, needed to utilize a large number of animals to obtain statistically significant results, and were unable to control the host environment after cell transplantation. Thus, we developed and characterized an in vitro system with which to efficiently screen compounds and techniques that might enhance the efficacy of stem cell therapy. 21 Using a serum-free media formulation, we developed a system whereby organotypic retinal explants from adult rats could be cultured for up to 17 days. We showed that tissue survival was good, as evidenced by prolonged cell survival, propidium iodide exclusion, low cleaved-caspase-3 labelling, and sustained immunoreactivity for a panel of neural retinal proteins. Importantly, retinal explants responded to coculture of either MIO-M1 cells or bone marrow-derived mesenchymal stromal cells (MSCs) on the vitreal surface in a manner very similar to whole eyes that received intravitreal cell injections. Endogenous Mü ller glia upregulated reactive intermediate filaments and the integration of grafted or co-cultured cells was blocked at the inner limiting membrane (ILM, Figure 1c) . Therefore, we concluded that this model could be used to screen interventions to enhance retinal integration of transplanted cells rapidly while utilizing only 1/8 the number of animals used for comparative in vivo experiments. 
Identifying and overcoming obstacles to intravitreal cell transplantation
Throughout our experiments, we have consistently observed that intravitreally transplanted cells can migrate into very close proximity with the inner retinal surface but rarely progress past the ILM. Having made a similar observation in retinal explant cultures, we used this system to identify the specific barrier obstructing grafted-cell integration. Initially, we mechanically peeled the ILM from the explant vitreal surface and confirmed immunohistochemically that the inner basal lamina was removed from portions of the tissue along with, in some cases, Mü ller cell endfeet. Importantly, ILM peeling before stem cell transplantation onto the vitreal surface resulted in a dramatic increase in the migration of engrafted cells into the retina, indicating that a major obstacle to cell migration exists within the ILM. We were curious, however, whether the specific barrier resided at the level of the basement membrane or at the glial endfeet. By independently disrupting each of these factors in isolation, using either enzymatic protein digestion or glial-specific toxins respectively, we determined that the integrity of the inner basal lamina is neither necessary nor sufficient to prevent grafted-cell infiltration into the retina. In contrast, suppression of Mü ller cell reactivity dramatically enhanced graft integration (Figure 1d ). It should be noted that the development of our in vitro retinal explant system was essential to show that basal lamina digestion did not enhance retinal graft migration because, unlike for the avascular chick retina, 22, 23 intravitreal injection of the proteolytic enzyme collagenase into rat eyes caused acute retinal haemorrhage, thereby severely limiting investigations in vivo.
Future directions
Although progress has been made in developing stem cell-based therapies for inner retinal disease, many barriers to clinical efficacy remain. Identifying ethical and clinically available sources for cells will require careful consideration. Although embryonic-and foetalderived stem cells have shown the capacity to generate retinal-like neurons [24] [25] [26] [27] [28] and confer retinal neuroprotection, 12, 29 ethical and logistic issues, including graft rejection resulting from inherent allogenic transplantation, will likely restrict their clinical utility. Various types of stem/progenitor cells exist in the adult mammalian body, including the eye, [30] [31] [32] [33] and further research into using these cells for transplantation is of interest. A newly revealed prospect exists in the use of induced pluripotent stem (iPS) cells, which can be produced from postmitotic adult tissue, such as skin, to create cells with properties similar to ES cells. 34, 35 Whether these cells will be useful for retinal stem cell therapy remains unknown. Regardless of the cell type chosen for transplantation, methods to safely control the terminal differentiation (for cell replacement) or bioactive factor secretion (for neuroprotection) must be further developed.
Although we have discussed methods to enhance the migration of transplanted cells into retinal tissue, further work is necessary. Modulation of the retinal environment to enhance graft integration should be optimized while minimizing disruption of normal retinal function. Furthermore, once engrafted cells can structurally integrate into the retina, they must then extend neurites and make synaptic connections with neighbouring cells. This will likely require the modulation of the notoriously inhibitory CNS environment. Treatment with chondroitinase ABC, for instance, digests chondroitin sulphate proteoglycans and enhances neurite outgrowth in the spinal cord 36 and in the retina. 17, 37 Combination treatments that promote migration, neurite growth, and synaptogenesis may be required for the full integration of transplanted cells. Thus, although formidable obstacles remain before cell transplantation will be used clinically to treat inner retinal disease, stepwise progress is leading us closer to protocols that may eventually demonstrate efficacy.
